Allarity Therapeutics, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
The Complaint asserts that, throughout the Class Period, the Defendants issued materially false and misleading statements concerning the Company’s business practices, operations, and adherence to compliance policies. Specifically, it contends that the Defendants inflated the ongoing regulatory prospects of the Dovitinib NDA and engaged in illegal, illicit, or otherwise improper conduct related to the Dovitinib NDA and/or the Dovitinib-DRP PMA, involving Allarity and three of its former officers. This misconduct exposed the Company to heightened risks of regulatory and governmental scrutiny, enforcement actions, and significant legal, financial, and reputational damages. Following the disclosure that Allarity was under investigation for wrongdoing related to the Dovitinib NDA and/or Dovitinib-DRP PMA, the Company downplayed the likelihood of an enforcement action resulting from the investigation. As a result, the Company’s public statements were materially false and misleading throughout the relevant period.
